We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GE HealthCare Q4 Earnings and Revenues Beat Estimates, Net Margin Falls
Read MoreHide Full Article
Key Takeaways
GEHC beat Q4 EPS and revenue estimates, with 7.1% reported sales growth and a 1.06x book-to-bill.
GEHC saw growth in Imaging, AVS and PDx, while Patient Care Solutions revenues fell year over year.
Net income margin fell 320 bps from tariffs and mix, even as volume and pricing benefits aided.
GE HealthCare (GEHC - Free Report) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.44, which beat the Zacks Consensus Estimate of $1.43 by 0.7%. However, the bottom line declined 0.7% year over year.
GAAP EPS in the quarter was $1.29, down 17.8% from the year-ago level.
For the full year, adjusted EPS was $4.59, up 2.2%. GAAP EPS rose 4.8% to $4.55.
Revenue Details
Revenues of $5.7 billion were up 7.1% year over year on a reported basis and 4.8% organically. The top line beat the Zacks Consensus Estimate by 1.9%. Total company orders increased 2% year over year organically. The book-to-bill was 1.06X, reflecting rising orders compared to shipments.
Revenues were supported by strong performance in the U.S. and EMEA markets, primarily across three segments — Pharmaceutical Diagnostics (PDx), Imaging and Advanced Visualization Solutions (“AVS”) — partially offset by a decline in the Patient Care Solutions segment.
For the full year, total revenues were up 4.8% to $20.6 billion. Organically, sales increased 3.5%.
GE HealthCare Technologies Inc. Price, Consensus and EPS Surprise
Revenues from this segment totaled $2.55 billion, up 6.6% year over year on a reported basis and 5.3% organically.
Segment EBIT was $264 million, down 12.5% year over year.
Advanced Visualization Solutions
Revenues totaled $1.53 billion, up 5.9% year over year on a reported basis and 4.2% organically.
Segment EBIT was $376 million, up 0.7% year over year.
Patient Care Solutions
Revenues amounted to $825 million, down 0.3% year over year on a reported basis and down 1.1% organically.
Segment EBIT was $74 million, down 29.6% year over year.
Pharmaceutical Diagnostics
Revenues totaled $790 million, up 22.3% year over year and 12.7% on an organic basis.
Segment EBIT was $234 million, up 10% year over year.
Margins
Net income margin was 10.3%, down 320 basis points from the prior-year level due to the unfavorable impact of tariffs and product mix, partially offset by benefits from volume and price.
Cumulative cash flow from operating activities at the end of the third quarter was $937 million compared with $1.96 billion a year ago.
Financial Position
GEHC exited the fourth quarter with cash, cash equivalents and investments of $4.51 billion compared with $4.03 billion in the previous quarter.
Total assets increased to $36.91 billion from $36.13 billion on a sequential basis.
2026 Guidance
GE HealthCare issued its organic revenue growth and adjusted EPS guidance for 2026.
The company expects organic revenue growth of 3-4% in 2026. It anticipates adjusted EPS to be in the range of $4.95-$5.15, implying 7.9-12.3% year-over-year growth. At current tariff rates, GEHC expects a lower impact in 2026 versus 2025. The Zacks Consensus Estimate for 2026 revenues and EPS is pegged at $21.38 billion and $4.94, respectively.
Our Take
GE HealthCare delivered robust fourth-quarter results, wherein both earnings and revenues beat estimates. The company’s strong quarterly performance was driven by healthy capital investment trends, optimized commercial execution and demand for new products. The strength in business performance was partially offset by continued unfavorable tariff impact. Although the unfavorable impact of tariffs is expected to continue in 2026, GEHC’s mitigation initiatives are likely to reduce the effect.
The company’s shares were up 3.5% in pre-market trading following a strong quarterly performance and better-than-expected EPS guidance for 2026. In the past six months, shares of the company have gained 11.5% against the industry’s 10.2% decline. The S&P 500 Index has risen 12.2% in the same period.
Image Source: Zacks Investment Research
GE HealthCare’s strong order book with a book-to-bill of 1.06 times implies continued demand for its products in 2026. The company is also focused on inorganic growth through acquisitions. It acquired Nihon Medi-Physics and icometrix in 2025, boosting its radiopharmaceutical and neurology portfolios, respectively. GEHC has signed an agreement to acquire Intelerad, with the deal expected to be closed in the first half of 2026. This buyout will advance the company’s cloud-enabled enterprise imaging across care settings.
Continued investment in R&D and new product introductions, such as advanced imaging systems and AI-enabled diagnostics, reflect GE HealthCare’s commitment to driving precision care and digital transformation in clinical workflows.
GEHC’s Zacks Rank & Stocks to Consider
GE HealthCare has a Zacks Rank #3 (Hold) at present.
Boston Scientific shares have lost 12% in the past six months. Estimates for the company’s fourth-quarter 2025 EPS have remained constant at 78 cents in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.36%. In the last reported quarter, it posted an earnings surprise of 5.63%.
Estimates for Phibro Animal Health’s second-quarter fiscal 2026 EPS have remained constant at 69 cents in the past 30 days. Shares of the company have risen 50.5% in the past six months compared with the industry’s 11.1% growth. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 20.77%. In the last reported quarter, it delivered an earnings surprise of 23.73%.
AtriCure shares have risen 5.2% in the past six months. Estimates for the company’s fourth-quarter 2025 loss per share have remained stable at 4 cents in the past 30 days. ATRC’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 67.06%. In the last reported quarter, it posted an earnings surprise of 90.91%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GE HealthCare Q4 Earnings and Revenues Beat Estimates, Net Margin Falls
Key Takeaways
GE HealthCare (GEHC - Free Report) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.44, which beat the Zacks Consensus Estimate of $1.43 by 0.7%. However, the bottom line declined 0.7% year over year.
GAAP EPS in the quarter was $1.29, down 17.8% from the year-ago level.
For the full year, adjusted EPS was $4.59, up 2.2%. GAAP EPS rose 4.8% to $4.55.
Revenue Details
Revenues of $5.7 billion were up 7.1% year over year on a reported basis and 4.8% organically. The top line beat the Zacks Consensus Estimate by 1.9%. Total company orders increased 2% year over year organically. The book-to-bill was 1.06X, reflecting rising orders compared to shipments.
Revenues were supported by strong performance in the U.S. and EMEA markets, primarily across three segments — Pharmaceutical Diagnostics (PDx), Imaging and Advanced Visualization Solutions (“AVS”) — partially offset by a decline in the Patient Care Solutions segment.
For the full year, total revenues were up 4.8% to $20.6 billion. Organically, sales increased 3.5%.
GE HealthCare Technologies Inc. Price, Consensus and EPS Surprise
GE HealthCare Technologies Inc. price-consensus-eps-surprise-chart | GE HealthCare Technologies Inc. Quote
Segmental Details
Imaging
Revenues from this segment totaled $2.55 billion, up 6.6% year over year on a reported basis and 5.3% organically.
Segment EBIT was $264 million, down 12.5% year over year.
Advanced Visualization Solutions
Revenues totaled $1.53 billion, up 5.9% year over year on a reported basis and 4.2% organically.
Segment EBIT was $376 million, up 0.7% year over year.
Patient Care Solutions
Revenues amounted to $825 million, down 0.3% year over year on a reported basis and down 1.1% organically.
Segment EBIT was $74 million, down 29.6% year over year.
Pharmaceutical Diagnostics
Revenues totaled $790 million, up 22.3% year over year and 12.7% on an organic basis.
Segment EBIT was $234 million, up 10% year over year.
Margins
Net income margin was 10.3%, down 320 basis points from the prior-year level due to the unfavorable impact of tariffs and product mix, partially offset by benefits from volume and price.
Cumulative cash flow from operating activities at the end of the third quarter was $937 million compared with $1.96 billion a year ago.
Financial Position
GEHC exited the fourth quarter with cash, cash equivalents and investments of $4.51 billion compared with $4.03 billion in the previous quarter.
Total assets increased to $36.91 billion from $36.13 billion on a sequential basis.
2026 Guidance
GE HealthCare issued its organic revenue growth and adjusted EPS guidance for 2026.
The company expects organic revenue growth of 3-4% in 2026. It anticipates adjusted EPS to be in the range of $4.95-$5.15, implying 7.9-12.3% year-over-year growth. At current tariff rates, GEHC expects a lower impact in 2026 versus 2025. The Zacks Consensus Estimate for 2026 revenues and EPS is pegged at $21.38 billion and $4.94, respectively.
Our Take
GE HealthCare delivered robust fourth-quarter results, wherein both earnings and revenues beat estimates. The company’s strong quarterly performance was driven by healthy capital investment trends, optimized commercial execution and demand for new products. The strength in business performance was partially offset by continued unfavorable tariff impact. Although the unfavorable impact of tariffs is expected to continue in 2026, GEHC’s mitigation initiatives are likely to reduce the effect.
The company’s shares were up 3.5% in pre-market trading following a strong quarterly performance and better-than-expected EPS guidance for 2026. In the past six months, shares of the company have gained 11.5% against the industry’s 10.2% decline. The S&P 500 Index has risen 12.2% in the same period.
Image Source: Zacks Investment Research
GE HealthCare’s strong order book with a book-to-bill of 1.06 times implies continued demand for its products in 2026. The company is also focused on inorganic growth through acquisitions. It acquired Nihon Medi-Physics and icometrix in 2025, boosting its radiopharmaceutical and neurology portfolios, respectively. GEHC has signed an agreement to acquire Intelerad, with the deal expected to be closed in the first half of 2026. This buyout will advance the company’s cloud-enabled enterprise imaging across care settings.
Continued investment in R&D and new product introductions, such as advanced imaging systems and AI-enabled diagnostics, reflect GE HealthCare’s commitment to driving precision care and digital transformation in clinical workflows.
GEHC’s Zacks Rank & Stocks to Consider
GE HealthCare has a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space are Boston Scientific Corporation (BSX - Free Report) , Phibro Animal Health (PAHC - Free Report) and AtriCure (ATRC - Free Report) , each presently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific shares have lost 12% in the past six months. Estimates for the company’s fourth-quarter 2025 EPS have remained constant at 78 cents in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.36%. In the last reported quarter, it posted an earnings surprise of 5.63%.
Estimates for Phibro Animal Health’s second-quarter fiscal 2026 EPS have remained constant at 69 cents in the past 30 days. Shares of the company have risen 50.5% in the past six months compared with the industry’s 11.1% growth. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 20.77%. In the last reported quarter, it delivered an earnings surprise of 23.73%.
AtriCure shares have risen 5.2% in the past six months. Estimates for the company’s fourth-quarter 2025 loss per share have remained stable at 4 cents in the past 30 days. ATRC’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 67.06%. In the last reported quarter, it posted an earnings surprise of 90.91%.